(Total Views: 231)
Posted On: 07/05/2017 7:28:48 PM
Post# of 72443
I think Keytruda's extra long half-life of 23 days had something to do with it. Revlimid's half-life is only 3 hours and Pomalyst's half-life is 7.5 hours in multiple myeloma patients.
That's why I think Kevetrin is a perfect candidate for combo therapies due it's short half-life and safety profile. Once its MOA is confirmed, we should see more trials involving K.
That's why I think Kevetrin is a perfect candidate for combo therapies due it's short half-life and safety profile. Once its MOA is confirmed, we should see more trials involving K.
Quote:
The failure of these combo therapies makes me hope that Kevetrin will work by itself, although we know that the company has talked about using it in a combo.
(3)
(0)
Scroll down for more posts ▼
